logo
  

KVH Industries Confirms Brent Bruun As President And CEO

KVH Industries, Inc., (KVHI) announced Wednesday that its Board of Directors has appointed Brent Bruun as President and Chief Executive Officer and a member of the Board. The Board also appointed two seasoned industry executives, David Kagan and David Tolley, as directors of KVH.

Bruun has served as KVH's interim President and Chief Executive Officer since March 2022. He also served as Chief Operating Officer of KVH beginning in 2016, as well as interim Chief Financial Officer of the Company.

Prior to that, Bruun was executive vice president of mobile broadband, senior vice president of global sales and business development, and vice president of global sales and business development.

He first joined KVH in 2008 and played a critical role in the growth of the Company's industry-leading mobile connectivity business.

Bruun previously served as senior vice president of strategic initiatives for SES AMERICOM, a satellite operator providing services via its fleet of 16 geosynchronous satellites covering North America. Earlier in his career, he held positions at KPMG LLP and General Electric.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
RELATED NEWS
Follow RTT